Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Recombinant human erythropoietin (EPO) supplementation is one method of treating neurodegenerative disease by reducing the generation of ROS.
|
31813204 |
2020 |
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Increasing evidence highlights the protective roles of erythropoietin (EPO) in neurodegenerative diseases and injuries of the central nervous system.
|
30535439 |
2019 |
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Erythropoietin (EPO), a hematopoietic factor, is one of the promising neuroprotective candidates in neurodegenerative disorders such as Alzheimer's disease (AD).
|
31493483 |
2019 |
Neurodegenerative Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Overall, the beneficial suppression of effector function via the N292G mutation may be offset by the deleterious effect this mutation has on the plasma levels of the TfRMAb-EPO fusion protein, especially following SQ administration, which is the preferred route of administration in humans for chronic neurodegenerative diseases including AD.
|
31199881 |
2019 |
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
However, penetration of the blood-brain barrier (BBB) and negative hematopoietic effects are the two major challenges for the therapeutic development of EPO for chronic neurodegenerative diseases like AD.
|
30656553 |
2019 |
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
However, the discovery of EPO and the EPO receptor (EPOR) in the nervous system may contribute to new treatment strategies for the use of EPO in neurodegenerative disorders.
|
30021390 |
2018 |
Neurodegenerative Disorders
|
0.400 |
AlteredExpression
|
group |
BEFREE |
As consequence recent novel therapeutic drugs for neurodegenerative diseases has led to the development of multi target drugs, that possess selective brain MAO A and B inhibitory moiety, iron chelating and antioxidant activities and the ability to increase brain levels of endogenous neurotrophins, such as BDNF, GDNF VEGF and erythropoietin and induce mitochondrial biogenesis.
|
30341696 |
2018 |
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Our results indicated that the BDNF-EPO-Shh novel-signaling pathway underlies the regulation of inflammatory responses and may be regarded as a potential therapeutic target in neurodegenerative diseases.
|
29427085 |
2018 |
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Our data suggest that EPO mediated regulation of Hbb supports neuronal energetics and may provide neuroprotection in MS and other neurodegenerative diseases where a dysfunction of mitochondria contributes to disease.
|
29498007 |
2018 |
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
The neuroprotective effects of erythropoietin (EPO) have been reported in some models of neurodegenerative disease, but because of its hematopoietic side effects, its derivatives lacking hematopoietic bioactivity is recommended.
|
30102955 |
2018 |
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
In conclusion, our results suggest that EpoL has a more potent neuroprotective profile than Epo against oxidative stress, mediated by activation of EpoR, thus EpoL represents an important target to develop a potential biopharmaceutical to treat different central nervous system pathologies related to oxidative stress such as stroke or neurodegenerative diseases.
|
28987867 |
2018 |
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
However, recent reports have demonstrated that EPO plays a neuroprotective role in the central nervous system, and EPO has been considered as a therapeutic target in neurodegenerative diseases such as ischemic stroke.
|
28817120 |
2017 |
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
In our study, we established a cellular material for future in vivo studies of neurodegenerative diseases based on EPO provided regionally at a nontoxic level.
|
26357589 |
2015 |
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
The hematopoietic cytokine erythropoietin (Epo) prevents neuronal death during ischemic events in the brain and in neurodegenerative diseases, presumably through its antiapoptotic effects.
|
16407271 |
2006 |
Neurodegenerative Disorders
|
0.400 |
Therapeutic
|
group |
CTD_human |
Astroglial cytoprotection by erythropoietin pre-conditioning: implications for ischemic and degenerative CNS disorders.
|
15816862 |
2005 |